Compositions and methods for detecting gastrointestinal pathogens
AssigneeGen-Probe Incorporated
InventorsNesreen H. BARAKAT, Sree D. PANUGANTI, Tamara J. JOHNSON
Life of this patent
Estimating the term…
Abstract
Disclosed are nucleic acid oligomers, including amplification oligomers and detection probes, for detection of Yersinia enterocolitica, Vibrio spp., Shiga Toxin Expressing E. coli (STEC) O157, and Plesiomonas shigelloides target nucleic acid. Also disclosed are methods of specific nucleic acid amplification and detection using the disclosed oligomers, as well as corresponding formulations, reaction mixtures, and kits. Methods of synthesizing the nucleic acid oligomers are also disclosed.
Claims40
(canceled)
A composition or kit for determining the presence or absence of at least one enteric pathogen in a sample, wherein the at least one enteric pathogen is selected from the group consisting of Yersinia enterocolitica, Vibrio spp., Shiga Toxin Expressing E. coli (STEC) O157, and Plesiomonas shigelloides, said composition or kit comprising a set of oligonucleotides comprising at least one of (a)-(d):
- (a) a Yersinia-specific amplification oligomer set capable of amplifying a target region of a Yersinia enterocolitica target nucleic acid, wherein the Yersinia-specific amplification oligomer set comprises first and second Yersinia-specific amplification oligomers respectively comprising target-hybridizing sequences as shown in (i) SEQ ID NO:26 and SEQ ID NO:46, including from 0 to 16 nucleotide analogs, (ii) SEQ ID NO:97 and SEQ ID NO:4, including from 0 to 16 nucleotide analogs, (iii) SEQ ID NO:
- 102 and SEQ ID NO:24, including from 0 to 16 nucleotide analogs, (iv) SEQ ID NO:6 and SEQ ID NO:24, including from 0 to 16 nucleotide analogs, (v) SEQ ID NO:
- 13 and SEQ ID NO:22, including from 0 to 16 nucleotide analogs, (vi) SEQ ID NO:77 and SEQ ID NO:22, including from 0 to 16 nucleotide analogs, (vii) SEQ ID NO:77 and SEQ ID NO:41, including from 0 to 16 nucleotide analogs, (viii) SEQ ID NO:28 and SEQ ID NO:30, including from 0 to 16 nucleotide analogs, (ix) SEQ ID NO:60 and SEQ ID NO:45, including from 0 to 16 nucleotide analogs, (x) SEQ ID NO:65 and SEQ ID NO:54, including from 0 to 16 nucleotide analogs, or (xi) SEQ ID NO:
- 10 and SEQ ID NO:4, including from 0 to 16 nucleotide analogs;
- (b) a Vibrio-specific amplification oligomer set capable of amplifying a target region of a Vibrio spp. target nucleic acid, wherein the Vibrio spp. is one or more of V. parahaemolyticus, V. vulnificus, and V. cholerae, and wherein the Vibrio-specific amplification oligomer set comprises
- (b-1) first and second V. parahaemolyticus-specific amplification oligomers respectively comprising target-hybridizing sequences as shown in (i) SEQ ID NO:51 and SEQ ID NO:76, including from 0 to 16 nucleotide analogs, (ii) SEQ ID NO:58 and SEQ ID NO:21, including from 0 to 16 nucleotide analogs, (iii) SEQ ID NO:58 and SEQ ID NO:
- 86, including from 0 to 16 nucleotide analogs, (iv) SEQ ID NO:53 and SEQ ID NO:
- 75, including from 0 to 16 nucleotide analogs, (v) SEQ ID NO:58 and SEQ ID NO:20, including from 0 to 16 nucleotide analogs, (vi) SEQ ID NO:52 and SEQ ID NO:75, including from 0 to 16 nucleotide analogs, (vii) SEQ ID NO:51 and SEQ ID NO:75, including from 0 to 16 nucleotide analogs, (viii) SEQ ID NO:52 and SEQ ID NO:76, including from 0 to 16 nucleotide analogs, or (ix) SEQ ID NO:53 and SEQ ID NO:76, including from 0 to 16 nucleotide analogs;
- and/or
- (b-2) first and second V. vulnificus-specific amplification oligomers respectively comprising target-hybridizing sequences as shown in (i) SEQ ID NO:66 and SEQ ID NO:62, including from 0 to 16 nucleotide analogs, (ii) SEQ ID NO:58 and SEQ ID NO:21, including from 0 to 16 nucleotide analogs, (iii) SEQ ID NO:42 and SEQ ID NO:37, including from 0 to 16 nucleotide analogs, (iv) SEQ ID NO:55 and SEQ ID NO:37, including from 0 to 16 nucleotide analogs, (v) SEQ ID NO:43 and SEQ ID NO:78, including from 0 to 16 nucleotide analogs, (vi) SEQ ID NO:58 and SEQ ID NO:20, including from 0 to 16 nucleotide analogs, (vii) SEQ ID NO:42 and SEQ ID NO:84, including from 0 to 16 nucleotide analogs, (viii) SEQ ID NO:42 and SEQ ID NO:47, including from 0 to 16 nucleotide analogs, (ix) SEQ ID NO:55 and SEQ ID NO:84, including from 0 to 16 nucleotide analogs, (x) SEQ ID NO:55 and SEQ ID NO:47, including from 0 to 16 nucleotide analogs, or (xi) SEQ ID NO:55 and SEQ ID NO:5, including from 0 to 16 nucleotide analogs;
- and/or
- (b-3) first and second V. cholerae-specific amplification oligomers respectively comprising target-hybridizing sequences as shown in (i) SEQ ID NO:56 and SEQ ID NO:
- 11, including from 0 to 16 nucleotide analogs, (ii) SEQ ID NO:32 and SEQ ID NO:3, including from 0 to 16 nucleotide analogs, (iii) SEQ ID NO:57 and SEQ ID NO:64, including from 0 to 16 nucleotide analogs, (iv) SEQ ID NO:94 and SEQ ID NO:
- 19, including from 0 to 16 nucleotide analogs, (v) SEQ ID NO:32 and SEQ ID NO:
- 105, including from 0 to 16 nucleotide analogs, (vi) SEQ ID NO:92 and SEQ ID NO:
- 3, including from 0 to 16 nucleotide analogs;
- (vii) SEQ ID NO:92 and SEQ ID NO:
- 105, including from 0 to 16 nucleotide analogs, (viii) SEQ ID NO:85 and SEQ ID NO:3, including from 0 to 16 nucleotide analogs, or (ix) SEQ ID NO:85 and SEQ ID NO:
- 105, including from 0 to 16 nucleotide analogs;
- (c) a STEC-specific amplification oligomer set capable of amplifying a target region of a STEC O157 target nucleic acid, wherein the STEC-specific amplification oligomer set comprises first and second STEC-specific amplification oligomers respectively comprising target-hybridizing sequences as shown in (i) SEQ ID NO:
- 70 and SEQ ID NO:
- 16, including from 0 to 16 nucleotide analogs, (ii) SEQ ID NO:93 and SEQ ID NO:101, including from 0 to 16 nucleotide analogs, (iii) SEQ ID NO:71 and SEQ ID NO:
- 44, including from 0 to 16 nucleotide analogs, (iv) SEQ ID NO:
- 90 and SEQ ID NO:
- 100, including from 0 to 16 nucleotide analogs, (v) SEQ ID NO:71 and SEQ ID NO:
- 16, including from 0 to 16 nucleotide analogs, (vi) SEQ ID NO:70 and SEQ ID NO:44, including from 0 to 16 nucleotide analogs, (vii) SEQ ID NO:70 and SEQ ID NO:
- 107, including from 0 to 16 nucleotide analogs, (viii) SEQ ID NO:70 and SEQ ID NO:87, including from 0 to 16 nucleotide analogs, (ix) SEQ ID NO:71 and SEQ ID NO:
- 107, including from 0 to 16 nucleotide analogs, or (x) SEQ ID NO:71 and SEQ ID NO:
- 87, including from 0 to 16 nucleotide analogs;
- and
- (d) a Plesiomonas-specific amplification oligomer set capable of amplifying a target region of a Plesiomonas shigelloides target nucleic acid, wherein the Plesiomonas-specific amplification oligomer set comprises first and second Plesiomonas-specific amplification oligomers respectively comprising target-hybridizing sequences as shown in (i) SEQ ID NO:2 and SEQ ID NO:49, including from 0 to 16 nucleotide analogs, (ii) SEQ ID NO:95 and SEQ ID NO:
- 1, including from 0 to 16 nucleotide analogs, (iii) SEQ ID NO:79 and SEQ ID NO:81, including from 0 to 16 nucleotide analogs, (iv) SEQ ID NO:
- 17 and SEQ ID NO:
- 1, including from 0 to 16 nucleotide analogs, (v) SEQ ID NO:95 and SEQ ID NO:
- 106, including from 0 to 16 nucleotide analogs, (vi) SEQ ID NO:
- 17 and SEQ ID NO:
- 106, including from 0 to 16 nucleotide analogs, (vii) SEQ ID NO:79 and SEQ ID NO:68, including from 0 to 16 nucleotide analogs, (viii) SEQ ID NO:
- 17 and SEQ ID NO:98, including from 0 to 16 nucleotide analogs, or (ix) SEQ ID NO:95 and SEQ ID NO:98, including from 0 to 16 nucleotide analogs.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
27-29. (canceled)
32-37. (canceled)
(canceled)
(canceled)
A method for determining the presence or absence of at least one enteric pathogen in a sample, wherein the at least one enteric pathogen is selected from the group consisting of Yersinia enterocolitica, Vibrio spp., Shiga Toxin Expressing E. coli (STEC) O157, and Plesiomonas shigelloides, the method comprising:
- (1) contacting a sample, said sample suspected of containing the at least one enteric pathogen, with an oligomer combination capable of amplifying a target region of Yersinia enterocolitica, Vibrio spp., STEC O157, and/or Plesiomonas shigelloides target nucleic acid, said oligomer combination comprising
- (a) a Yersinia-specific amplification oligomer set capable of amplifying a target region of a Yersinia enterocolitica target nucleic acid, wherein the Yersinia-specific amplification oligomer set comprises first and second Yersinia-specific amplification oligomers respectively comprising target-hybridizing sequences as shown in (i) SEQ ID NO:26 and SEQ ID NO:46, including from 0 to 16 nucleotide analogs, (ii) SEQ ID NO:97 and SEQ ID NO:
- 4, including from 0 to 16 nucleotide analogs, (iii) SEQ ID NO:
- 102 and SEQ ID NO:
- 24, including from 0 to 16 nucleotide analogs, (iv) SEQ ID NO:6 and SEQ ID NO:24, including from 0 to 16 nucleotide analogs, (v) SEQ ID NO:
- 13 and SEQ ID NO:22, including from 0 to 16 nucleotide analogs, (vi) SEQ ID NO:77 and SEQ ID NO:22, including from 0 to 16 nucleotide analogs, (vii) SEQ ID NO:77 and SEQ ID NO:41, including from 0 to 16 nucleotide analogs, (viii) SEQ ID NO:28 and SEQ ID NO:30, including from 0 to 16 nucleotide analogs, (ix) SEQ ID NO:60 and SEQ ID NO:45, including from 0 to 16 nucleotide analogs, (x) SEQ ID NO:65 and SEQ ID NO:54, including from 0 to 16 nucleotide analogs, or (xi) SEQ ID NO:
- 10 and SEQ ID NO:4, including from 0 to 16 nucleotide analogs;
- and/or
- (b) a Vibrio-specific amplification oligomer set capable of amplifying a target region of a Vibrio spp. target nucleic acid, wherein the Vibrio spp. is one or more of V. parahaemolyticus, V. vulnifcus, and V. cholerae, and wherein the Vibrio-specific amplification oligomer set comprises
- (b-1) first and second V. parahaemolyticus-specific amplification oligomers respectively comprising target-hybridizing sequences as shown in (i) SEQ ID NO:51 and SEQ ID NO:76, including from 0 to 16 nucleotide analogs, (ii) SEQ ID NO:58 and SEQ ID NO:21, including from 0 to 16 nucleotide analogs, (iii) SEQ ID NO:58 and SEQ ID NO:86, including from 0 to 16 nucleotide analogs, (iv) SEQ ID NO:53 and SEQ ID NO:75, including from 0 to 16 nucleotide analogs, (v) SEQ ID NO:58 and SEQ ID NO:20, including from 0 to 16 nucleotide analogs, (vi) SEQ ID NO:52 and SEQ ID NO:75, including from 0 to 16 nucleotide analogs, (vii) SEQ ID NO:51 and SEQ ID NO:75, including from 0 to 16 nucleotide analogs, (viii) SEQ ID NO:52 and SEQ ID NO:76, including from 0 to 16 nucleotide analogs, or (ix) SEQ ID NO:53 and SEQ ID NO:76, including from 0 to 16 nucleotide analogs;
- and/or
- (b-2) first and second V. vulnificus-specific amplification oligomers respectively comprising target-hybridizing sequences as shown in (i) SEQ ID NO:66 and SEQ ID NO:62, including from 0 to 16 nucleotide analogs, (ii) SEQ ID NO:58 and SEQ ID NO:21, including from 0 to 16 nucleotide analogs, (iii) SEQ ID NO:42 and SEQ ID NO:37, including from 0 to 16 nucleotide analogs, (iv) SEQ ID NO:55 and SEQ ID NO:37, including from 0 to 16 nucleotide analogs, (v) SEQ ID NO:43 and SEQ ID NO:78, including from 0 to 16 nucleotide analogs, (vi) SEQ ID NO:58 and SEQ ID NO:20, including from 0 to 16 nucleotide analogs, (vii) SEQ ID NO:42 and SEQ ID NO:84, including from 0 to 16 nucleotide analogs, (viii) SEQ ID NO:42 and SEQ ID NO:47, including from 0 to 16 nucleotide analogs, (ix) SEQ ID NO:55 and SEQ ID NO:84, including from 0 to 16 nucleotide analogs, (x) SEQ ID NO:55 and SEQ ID NO:47, including from 0 to 16 nucleotide analogs, or (xi) SEQ ID NO:55 and SEQ ID NO:5, including from 0 to 16 nucleotide analogs;
- and/or
- (b-3) first and second V. cholerae-specific amplification oligomers respectively comprising target-hybridizing sequences as shown in (i) SEQ ID NO:56 and SEQ ID NO:
- 11, including from 0 to 16 nucleotide analogs, (ii) SEQ ID NO:32 and SEQ ID NO:3, including from 0 to 16 nucleotide analogs, (iii) SEQ ID NO:57 and SEQ ID NO:64, including from 0 to 16 nucleotide analogs, (iv) SEQ ID NO:94 and SEQ ID NO:
- 19, including from 0 to 16 nucleotide analogs, (v) SEQ ID NO:32 and SEQ ID NO:
- 105, including from 0 to 16 nucleotide analogs, (vi) SEQ ID NO:92 and SEQ ID NO:3, including from 0 to 16 nucleotide analogs;
- (vii) SEQ ID NO:92 and SEQ ID NO:
- 105, including from 0 to 16 nucleotide analogs, (viii) SEQ ID NO:85 and SEQ ID NO:3, including from 0 to 16 nucleotide analogs, or (ix) SEQ ID NO:85 and SEQ ID NO:
- 105, including from 0 to 16 nucleotide analogs;
- and/or
- (c) a STEC-specific amplification oligomer set capable of amplifying a target region of a STEC O157 target nucleic acid, wherein the STEC-specific amplification oligomer set comprises first and second STEC-specific amplification oligomers respectively comprising target-hybridizing sequences as shown in (i) SEQ ID NO:70 and SEQ ID NO:
- 16, including from 0 to 16 nucleotide analogs, (ii) SEQ ID NO:93 and SEQ ID NO:101, including from 0 to 16 nucleotide analogs, (iii) SEQ ID NO:71 and SEQ ID NO:44, including from 0 to 16 nucleotide analogs, (iv) SEQ ID NO:90 and SEQ ID NO:
- 100, including from 0 to 16 nucleotide analogs, (v) SEQ ID NO:71 and SEQ ID NO:
- 16, including from 0 to 16 nucleotide analogs, (vi) SEQ ID NO:70 and SEQ ID NO:44, including from 0 to 16 nucleotide analogs, (vii) SEQ ID NO:70 and SEQ ID NO:
- 107, including from 0 to 16 nucleotide analogs, (viii) SEQ ID NO:70 and SEQ ID NO:87, including from 0 to 16 nucleotide analogs, (ix) SEQ ID NO:71 and SEQ ID NO:
- 107, including from 0 to 16 nucleotide analogs, or (x) SEQ ID NO:71 and SEQ ID NO:87, including from 0 to 16 nucleotide analogs;
- and/or
- (d) a Plesiomonas-specific amplification oligomer set capable of amplifying a target region of a Plesiomonas shigelloides target nucleic acid, wherein the Plesiomonas-specific amplification oligomer set comprises first and second Plesiomonas-specific amplification oligomers respectively comprising target-hybridizing sequences as shown in (i) SEQ ID NO:2 and SEQ ID NO:49, including from 0 to 16 nucleotide analogs, (ii) SEQ ID NO:95 and SEQ ID NO:
- 1, including from 0 to 16 nucleotide analogs, (iii) SEQ ID NO:79 and SEQ ID NO:81, including from 0 to 16 nucleotide analogs, (iv) SEQ ID NO:
- 17 and SEQ ID NO:
- 1, including from 0 to 16 nucleotide analogs, (v) SEQ ID NO:95 and SEQ ID NO:
- 106, including from 0 to 16 nucleotide analogs, (vi) SEQ ID NO:
- 17 and SEQ ID NO:
- 106, including from 0 to 16 nucleotide analogs, (vii) SEQ ID NO:79 and SEQ ID NO:68, including from 0 to 16 nucleotide analogs, (viii) SEQ ID NO:
- 17 and SEQ ID NO:98, including from 0 to 16 nucleotide analogs, or (ix) SEQ ID NO:95 and SEQ ID NO:98, including from 0 to 16 nucleotide analogs;
- (2) performing an in vitro nucleic acid amplification reaction, wherein any Yersinia enterocolitica, Vibrio spp., STEC O157, and/or Plesiomonas shigelloides target nucleic acid present in the sample is used as a template for generating one or more amplification products corresponding to the Yersinia enterocolitica, Vibrio spp., STEC O157, and/or Plesiomonas shigelloides target regions;
- and
- (3) detecting the presence or absence of the one or more amplification products, thereby determining the presence or absence of the at least one enteric pathogen in the sample.
(canceled)
(canceled)
(canceled)
A method for synthesizing a pair of oligonucleotides, comprising synthesizing a first oligonucleotide and synthesizing a second oligonucleotide,
- wherein each of the synthesizing the first oligonucleotide and the synthesizing the second oligonucleotide comprises the steps of:
- (a) obtaining a solid support comprising at least one nucleobase residue, wherein the at least one nucleobase residue is covalently bound at a 3′ position to the solid support;
- (b) coupling a 5′ position of the nucleobase residue furthest from the solid support to a 3′ position of another nucleobase residue;
- (c) repeating step (b) at least 16 additional times, thereby generating at least 18 contiguous nucleobase residues coupled to the solid support;
- and
- (d) cleaving the at least 18 contiguous nucleobase residues generated in step (c), thereby obtaining the oligonucleotide, and
- wherein the first oligonucleotide and the second oligonucleotide respectively comprise the nucleotide sequences of any one of
- SEQ ID NO:26 and SEQ ID NO:46, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:97 and SEQ ID NO:4, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:
- 102 and SEQ ID NO:24, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:6 and SEQ ID NO:24, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:
- 13 and SEQ ID NO:22, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:77 and SEQ ID NO:22, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:77 and SEQ ID NO:41, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:28 and SEQ ID NO:30, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:60 and SEQ ID NO:45, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:65 and SEQ ID NO:54, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:
- 10 and SEQ ID NO:4, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:51 and SEQ ID NO:76, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:58 and SEQ ID NO:21, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:58 and SEQ ID NO:86, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:53 and SEQ ID NO:75, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:58 and SEQ ID NO:20, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:52 and SEQ ID NO:75, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:51 and SEQ ID NO:75, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:52 and SEQ ID NO:76, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:53 and SEQ ID NO:76, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:66 and SEQ ID NO:62, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:58 and SEQ ID NO:21, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:42 and SEQ ID NO:37, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:55 and SEQ ID NO:37, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:43 and SEQ ID NO:78, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:58 and SEQ ID NO:20, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:42 and SEQ ID NO:84, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:42 and SEQ ID NO:47, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:55 and SEQ ID NO:84, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:55 and SEQ ID NO:47, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:55 and SEQ ID NO:5, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:56 and SEQ ID NO:
- 11, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:32 and SEQ ID NO:3, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:57 and SEQ ID NO:64, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:94 and SEQ ID NO:
- 19, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:32 and SEQ ID NO:
- 105, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:92 and SEQ ID NO:3, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:92 and SEQ ID NO:
- 105, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:85 and SEQ ID NO:3, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:85 and SEQ ID NO:
- 105, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:70 and SEQ ID NO:
- 16, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:93 and SEQ ID NO:101, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:71 and SEQ ID NO:44, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:90 and SEQ ID NO:
- 100, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:71 and SEQ ID NO:
- 16, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:70 and SEQ ID NO:44, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:70 and SEQ ID NO:
- 107, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:70 and SEQ ID NO:87, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:71 and SEQ ID NO:
- 107, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:71 and SEQ ID NO:87, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:2 and SEQ ID NO:49, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:95 and SEQ ID NO:
- 1, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:79 and SEQ ID NO:81, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:
- 17 and SEQ ID NO:
- 1, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:95 and SEQ ID NO:
- 106, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:
- 17 and SEQ ID NO:
- 106, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:79 and SEQ ID NO:68, including from 0 to 16 nucleotide analogs;
- SEQ ID NO:
- 17 and SEQ ID NO:98, including from 0 to 16 nucleotide analogs;
- or
- SEQ ID NO:95 and SEQ ID NO:98, including from 0 to 16 nucleotide analogs.
Dependencies are inferred from the claim text.